Nephrectomy — kidney removal surgery, and what to expect

A nephrectomy is an operation to remove a kidney tumour. The word covers two quite different operations. A partial nephrectomy takes out the tumour and a rim of tissue around it and leaves the rest of the kidney working — this is the preferred operation for most small tumours. A radical nephrectomy removes the whole kidney together with the fat around it, and is used when the tumour is large, centrally placed or too involved for the kidney to be saved. Either can be reached through an open incision, through keyhole incisions, or robotically. So the word covers two separate decisions: how much kidney comes out, and how the surgeon gets to it.

Yes. One healthy kidney can do the work of two, and most people who have a kidney removed return to normal daily life, work and exercise. That is why living kidney donation is possible at all. What changes is that the remaining kidney is now the only one you have, so it is looked after deliberately: kidney function and blood pressure are checked at follow-up, blood pressure and diabetes are controlled properly, dehydration is avoided, and routine anti-inflammatory painkillers are used sparingly and on advice. If your kidney function was already reduced before surgery, or the other kidney is not healthy, that is one of the strongest arguments for kidney-sparing surgery instead.

Neither is better in the abstract — the tumour decides. For a small tumour sitting where it can be removed safely, NCCN guidance favours a partial nephrectomy, because sparing working kidney tissue protects long-term kidney function without giving up cancer control. For a large, central or vein-involved tumour, or where sparing the kidney would compromise the cancer operation, a radical nephrectomy is the right answer and trying to spare tissue would be the wrong one. Size, depth, position relative to the collecting system and the vessels, the health of the other kidney and your own fitness all feed into it, and the case is reviewed at a uro-oncology tumour board before anything is booked.

It depends on which operation you have and how it is done, so no honest answer is a single number. Keyhole and robotic surgery generally mean a shorter hospital stay, less pain and an earlier return to normal activity than an open operation, and a partial nephrectomy and a radical nephrectomy do not recover identically either. Your surgical team will give you a realistic timeline for your own operation before you consent to it, including when you can drive, lift and go back to work. What is consistent is the shape of it: walking early, breathing exercises, no heavy lifting while the wound heals, and a check on kidney function afterwards.

Chemotherapy is not the main treatment for kidney cancer — renal cell carcinoma is largely resistant to it, which is why it is rarely offered. For most people whose cancer was confined to the kidney, the operation is the whole treatment, and what follows is a surveillance schedule rather than more therapy. Where the pathology shows features carrying a higher risk of the cancer returning, adjuvant immunotherapy with an immune checkpoint inhibitor may be discussed after surgery. If disease is already advanced, systemic treatment leads and surgery plays a supporting role — checkpoint inhibitor combinations, or targeted therapy that blocks tumour blood-vessel signalling.

No, and we would rather say so plainly. Kidney surgery of every kind — partial, radical, laparoscopic, robotic and cytoreductive nephrectomy — along with tumour ablation and PET-CT, is delivered at specialist urology, uro-oncology and interventional radiology partner centres. CION coordinates it: we review your scans, take your case to a tumour board, refer you to the right surgical team and handle everything around the operation. What is medical-oncology led and in-house at CION is the diagnostic workup, systemic therapy including immunotherapy and targeted therapy, radiation planning, post-surgery surveillance and survivorship care.